Endo Unit Shutdown Could Strand Incontinence Treatment Praised By FDA Panel
This article was originally published in Clinica
Executive Summary
Astora Women's Health's TOPAS treatment for fecal incontinence seemed headed to market after FDA’s Gastroenterology and Urology Devices Panel unanimously recommended approval on Feb. 25. The mesh implant would be the first device of its kind to treat the difficult and socially isolating condition, which some estimates say affects up to 22% of women older than 60.